Based on a TGF-β-inducible reporter system, Zhang et, al. showed that the TGF-β receptor kinase inhibitor LY2109761 inhibited CRLM by blocking the tumor promoting function of TGF-β in vivo [208]. This evidence concerns the gene TGFB1 and neoplasm.